In the Phase 1 clinical trial in men with mCRPC, ARV-110 continues to show promising activity in a very late-line population, with PSA reductions >50% observed at doses greater than 280 mg, the last reported cohort. In the dose escalation, ARV-110 exposures have risen dose proportionally,...
ARV-471 是一种用于乳腺癌的口服雌激素受体 PROTAC 蛋白降解剂。ARV-471 是一种异双功能分子,可促进雌激素受体 α 和细胞内 E3 连接酶复合物之间的相互作用。ARV-471 通过蛋白酶体导致雌激素受体的泛素化和随后的降解。ARV-471 可强力降解 ER 阳性乳腺癌细胞系中的 ER,DC50值约为 2 nM。 ARV-471Chemical...
About Arvinas Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas ...
除了针对已验证靶点和“不可成药”靶点开发出了强大的PROTAC®蛋白质降解剂的临床前管线外,Arvinas还有3个临床阶段项目:bavdegalutamide(ARV-110)和ARV-766用于治疗转移性去势抵抗前列腺癌(mCRPC),ARV-471治疗局部晚期或转移性ER+/HER2-乳腺癌。 2021年7月,辉瑞与Arvinas达成一项全球合作,开发和商业化ARV-471。...
In the Phase 1 clinical trial in men with mCRPC, ARV-110 continues to show promising activity in a very late-line population, with PSA reductions >50% observed at doses greater than 280 mg, the last reported cohort. In the dose escalation, ARV-110 exposures have risen dose proportionally,...